Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pramipexole - Boehringer Ingelheim

Next Previous
Search
Drug Profile

Pramipexole - Boehringer Ingelheim

Alternative Names: BI-Sifrol; Daquiran; Mirapex; Mirapex ER; Mirapex LA; Mirapexin; Pexola; Pramipexole extended-release - Boehringer Ingelheim; Sifrol; Sirfrol ER; SND 919; SND 919Y

Latest Information Update: 02 Sep 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Boehringer Ingelheim
  • Class Antidepressants; Antiparkinsonians; Benzothiazoles; Small molecules
  • Mechanism of Action Dopamine D2 receptor agonists; Dopamine D3 receptor agonists; Dopamine D4 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Parkinson's disease; Restless legs syndrome
  • No development reported Myoclonus
  • Discontinued Fibromyalgia; Gilles de la Tourette's syndrome; Schizophrenia

Most Recent Events

  • 12 Aug 2024 Boehringer Ingelheim completes a phase I bioequivalence trial (In volunteers) (PO) (NCT06457204)
  • 27 Jun 2024 Phase-I clinical trials in Parkinson's disease (In volunteers) in Germany (PO) (NCT06457204)
  • 13 Jun 2024 Boehringer Ingelheim plans a phase I trial (In volunteers) (PO) (NCT06457204)

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top